Trials / Recruiting
RecruitingNCT06805552
Sarcopenia and Systemic Therapy in HCC
Prognostic Model of Survival of Patients With Hepatocarcinoma and Sarcopenia Treated With Systemic Therapy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 270 (estimated)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.
Detailed description
The impact of sarcopenia will be assessed 12 months after the start of chemotherapy. Additionally, other factors affecting prognosis will be investigated to develop a specific predictive model for the risk of death at 12 months. Finally, an external validation of this predictive model for the risk of death will be carried out.
Conditions
Timeline
- Start date
- 2022-10-19
- Primary completion
- 2025-11-01
- Completion
- 2025-11-01
- First posted
- 2025-02-03
- Last updated
- 2025-02-03
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06805552. Inclusion in this directory is not an endorsement.